(Q38807880)

6 September 2017

title

Inhibition of epithelial-mesenchymal transition in bladder cancer cells via modulation of mTOR signalling (English)

1 reference

6 September 2017

Banu Iskender

1

1 reference

6 September 2017

Kenan Izgi

2

1 reference

6 September 2017

Esra Hizar

3

1 reference

6 September 2017

Johann Jauch

4

1 reference

6 September 2017

Aslihan Arslanhan

5

1 reference

6 September 2017

Esra Hilal Yuksek

6

1 reference

6 September 2017

Halit Canatan

7

1 reference

6 September 2017

publication date

30 December 2015

1 reference

6 September 2017

1 reference

6 September 2017

volume

37

1 reference

6 September 2017

issue

6

1 reference

6 September 2017

page(s)

8281-8291

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-015-4695-1

6 September 2017

exact match

0 references

cites work

Molecular mechanisms of epithelial-mesenchymal transition

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Epithelial-mesenchymal transitions in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Regulatory networks defining EMT during cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

TGF-β signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

The evolution of the TOR pathway and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Common corruption of the mTOR signaling network in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

mTOR inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

The interplay between Src family kinases and receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Src kinase contributes to the metastatic spread of carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

The src-family kinase inhibitor PP2 suppresses the in vitro invasive phenotype of bladder carcinoma cells via modulation of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Dual induction of mitochondrial apoptosis and senescence in chronic myelogenous leukemia by myrtucommulone A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Myrtucommulone-A treatment decreases pluripotency- and multipotency-associated marker expression in bladder cancer cell line HTB-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Myrtucommulone-A Induces both Extrinsic and Intrinsic Apoptotic Pathways in Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Thymoquinone: fifty years of success in the battle against cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Identification of drugs as single agents or in combination to prevent carcinoma dissemination in a microfluidic 3D environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Benzidine induces epithelial-mesenchymal transition in human uroepithelial cells through ERK1/2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Biomarkers for epithelial-mesenchymal transitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Crosstalk of Oncogenic Signaling Pathways during Epithelial-Mesenchymal Transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

TGF-β-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

The mTOR signalling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Lkb1 and Pten synergise to suppress mTOR-mediated tumorigenesis and epithelial-mesenchymal transition in the mouse bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Establishment of two new human bladder carcinoma cell lines, CAL 29 and CAL 185. Comparative study of cell scattering and epithelial to mesenchyme transition induced by growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Thymoquinone inhibits tumor growth and induces apoptosis in a breast cancer xenograft mouse model: the role of p38 MAPK and ROS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Thymoquinone inhibits proliferation and invasion of human nonsmall-cell lung cancer cells via ERK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4695-1

Dual inhibition by S6K1 and Elf4E is essential for controlling cellular growth and invasion in bladder cancer

21 January 2018

1 reference

12 December 2020

Src signaling in cancer invasion

1 reference

12 December 2020

Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).

1 reference

12 December 2020

Inhibition of tobacco smoke-induced bladder MAPK activation and epithelial-mesenchymal transition in mice by curcumin

1 reference

12 December 2020

AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells.

1 reference

12 December 2020

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

1 reference

12 December 2020

Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.

1 reference

12 December 2020

Regulation of SRC family kinases in human cancers

1 reference

12 December 2020

10.1007/S13277-015-4695-1

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1048060947

0 references

1 reference